Case Commentary: Extending our therapeutic range against multidrug-resistant Candida

Max W. Adelman; David R. Andes

doi:10.1128/aac.00847-24

Case Commentary: Extending our therapeutic range against multidrug-resistant Candida

Research output: Contribution to journal › Review article › peer-review

Abstract

Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.

Original language	English (US)
Journal	Antimicrobial Agents and Chemotherapy
Volume	68
Issue number	8
DOIs	https://doi.org/10.1128/aac.00847-24
State	Published - Aug 1 2024

Keywords

antifungal agents
antifungal resistance
antifungal therapy
Candida
endocarditis
osteomyelitis

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/aac.00847-24

Cite this

@article{f0e67006687f434685beb74986647368,

title = "Case Commentary: Extending our therapeutic range against multidrug-resistant Candida",

abstract = "Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.",

keywords = "antifungal agents, antifungal resistance, antifungal therapy, Candida, endocarditis, osteomyelitis",

author = "Adelman, {Max W.} and Andes, {David R.}",

year = "2024",

month = aug,

day = "1",

doi = "10.1128/aac.00847-24",

language = "English (US)",

volume = "68",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Case Commentary

T2 - Extending our therapeutic range against multidrug-resistant Candida

AU - Adelman, Max W.

AU - Andes, David R.

PY - 2024/8/1

Y1 - 2024/8/1

N2 - Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.

AB - Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.

KW - antifungal agents

KW - antifungal resistance

KW - antifungal therapy

KW - Candida

KW - endocarditis

KW - osteomyelitis

UR - http://www.scopus.com/inward/record.url?scp=85200938693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85200938693&partnerID=8YFLogxK

U2 - 10.1128/aac.00847-24

DO - 10.1128/aac.00847-24

M3 - Review article

C2 - 39037274

AN - SCOPUS:85200938693

SN - 0066-4804

VL - 68

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

ER -

Case Commentary: Extending our therapeutic range against multidrug-resistant Candida

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this